 Noonan syndrome NS is a rare genetic disease incidence 12500 live births characterized by the association of craniofacial manifestations, cardiopathies, short stature, and tumor predisposition. The genetic causes of Noonan Syndrome are mutations of genes involved in the RasMitogen-Activated Protein Kinases MAPK pathway, mainly the gene encoding the tyrosine phosphatase Shp2 50 of patients.Shp2 appears to be involved in many facets of energy metabolism control glucose homeostasis, adipose tissue function..., through mechanisms that are poorly understood. Several metabolic anomalies reduced adiposity, improved glucose tolerance have been recently identified in an original mouse model carrying Shp2 mutation. Moreover, recent clinical survey has shown that adult Noonan Syndrome patients are protected from developping overweight and obesity when compared to the general population. However, the metabolic status associated with Noonan Syndrome condition has not been explored to date. 